The results reported by Aché in 2009, combined with above-market growth in key segments, were achieved based on the combination of sound planning, careful monitoring, and flexibility to manage the day-to-day business. To reach this performance, we blended skills built over four decades, with the strategic vision and experience of our executive officers, and agility in identifying new opportunities.

More than the consolidation of a growth trend, Aché’s excellent performance for the year aims at a future full of possibilities. We are prepared to respond to the comprehensive changes experienced by the health sector in Brazil, which presents a new profile with the expansion of income and, consequently, of the domestic market, the expiration of patents on branded drugs, and the growing demand for quality at competitive prices by consumers and health professionals alike.

As a Brazilian company, whose competitive edge were shaped by the specific conditions of the domestic market, Aché is able to respond positively to this new scenario. In line with this, it is based on the expertise in developing branded generics, on the penetration and strength of its sales forces, on the establishment of a culture of research and innovation, on the ability to establish strategic partnerships, on a qualified and high-valued team, and on modern, efficient facilities.

In 2007, we repositioned products and prices; 2008 was the year for expansion of promotional investment; and in 2009, we were able to reap the fruits of our work, through revenue growth and significant increase in cash low.

Correct portfolio management plays a fundamental role. In 2009, two product launches represented the wisdom of the strategy: antidepressant Exodus, which made affordable a leading-edge treatment, and Meritor, an innovative product for the treatment of diabetes, the result of valuable international partnerships. It is worth mentioning that 155 projects of new drugs are currently underway, with the potential to expand by 40% the company’s revenues by 2012.

Advancements in the expansion of revenues and the ability to maintain the company’s value creation endorse the current studies for a possible initial public offering. The proposal to expand the shareholder base has the primary purpose of enabling Aché to perform as a world-class company and to strengthen the foundation for its perpetuation.

We are also proud to say that the most spoken word by employees at the end of 2009 was “opportunity”. We are convinced that the company is fulfilling its social objectives by creating opportunities for employees, health solutions for its partners and consumers, and added value for its shareholders.